146 related articles for article (PubMed ID: 28465101)
1. Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
Wei L; Wang HL; Huang L; Chen CH; Morris-Natschke SL; Lee KH; Xie L
Bioorg Med Chem Lett; 2017 Jun; 27(12):2788-2792. PubMed ID: 28465101
[TBL] [Abstract][Full Text] [Related]
2. Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.
Liu N; Wei L; Huang L; Yu F; Zheng W; Qin B; Zhu DQ; Morris-Natschke SL; Jiang S; Chen CH; Lee KH; Xie L
J Med Chem; 2016 Apr; 59(8):3689-704. PubMed ID: 27070547
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Liu N; Qin B; Sun LQ; Yu F; Lu L; Jiang S; Lee KH; Xie L
Bioorg Med Chem Lett; 2014 Aug; 24(16):3719-23. PubMed ID: 25042339
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Sun LQ; Qin B; Huang L; Qian K; Chen CH; Lee KH; Xie L
Bioorg Med Chem Lett; 2012 Apr; 22(7):2376-9. PubMed ID: 22406117
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
Sun LQ; Zhu L; Qian K; Qin B; Huang L; Chen CH; Lee KH; Xie L
J Med Chem; 2012 Aug; 55(16):7219-29. PubMed ID: 22856541
[TBL] [Abstract][Full Text] [Related]
6. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
[TBL] [Abstract][Full Text] [Related]
7. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
8. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Singh AK; De Wijngaert B; Bijnens M; Uyttersprot K; Nguyen H; Martinez SE; Schols D; Herdewijn P; Pannecouque C; Arnold E; Das K
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2203660119. PubMed ID: 35858448
[TBL] [Abstract][Full Text] [Related]
10. M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Oliveira M; Brenner BG; Xu H; Ibanescu RI; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2017 Nov; 72(11):3008-3011. PubMed ID: 28961903
[TBL] [Abstract][Full Text] [Related]
11. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided design of novel biphenyl-quinazoline derivatives as potent non-nucleoside reverse transcriptase inhibitors featuring improved anti-resistance, selectivity, and solubility.
Wang JS; Zhao KX; Zhang K; Pannecouque C; De Clercq E; Wang S; Chen FE
Bioorg Chem; 2024 Jun; 147():107340. PubMed ID: 38593532
[TBL] [Abstract][Full Text] [Related]
13. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
Kulkarni R; Babaoglu K; Lansdon EB; Rimsky L; Van Eygen V; Picchio G; Svarovskaia E; Miller MD; White KL
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):47-54. PubMed ID: 21997204
[TBL] [Abstract][Full Text] [Related]
14. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Tian X; Qin B; Wu Z; Wang X; Lu H; Morris-Natschke SL; Chen CH; Jiang S; Lee KH; Xie L
J Med Chem; 2010 Dec; 53(23):8287-97. PubMed ID: 21049929
[TBL] [Abstract][Full Text] [Related]
16. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
Qin B; Jiang X; Lu H; Tian X; Barbault F; Huang L; Qian K; Chen CH; Huang R; Jiang S; Lee KH; Xie L
J Med Chem; 2010 Jul; 53(13):4906-16. PubMed ID: 20527972
[TBL] [Abstract][Full Text] [Related]
17. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
[TBL] [Abstract][Full Text] [Related]
19. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
[TBL] [Abstract][Full Text] [Related]
20. Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
Chen X; Ding L; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
Eur J Med Chem; 2020 Sep; 202():112549. PubMed ID: 32712537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
